Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like.
The affordable meningitis A vaccine, MenAfriVac, has been given to millions of people in Africa's so-called "meningitis belt," and is about to be administered to even more. The World Health Organization approved the shot, previously approved for people aged one to 29, for use in the routine immunization of infants less than one year old in sub-Saharan Africa.
The new nod could boost sales of the French drugmaker's vaccine, a lift it could use after Menactra's top-line haul in 2013 sank to €424 million in a 21.5% slide.
Pfizer and Novartis have been racing to get their meningitis B vaccines to market for years. But as of Tuesday, the contest has never been closer, with both companies submitting approval applications to the FDA. Now, it's up to the agency to decide which shot gets the green light first--and first crack at the wide-open patient pool that comes with it.
Both Pfizer and Novartis have picked up the FDA's much-coveted breakthrough-therapy designation for their meningitis B vaccines, and now the rivals have chosen the same day to submit their injections for approval, leaving it up to regulators which will hit the market first.
When looking for celebrity spokespeople, pharma companies want someone who can deliver a health message as a peer might. And for Sanofi, which is trying to spread the word about the importance of meningitis booster shots--amid lagging sales of its vaccines for the deadly disease--that person is 12-time Olympic medalist swimmer Dara Torres.
According to a new survey, more than two in three mothers have little to no knowledge of the CDC's recommendations for preventing meningococcal meningitis. And if you're a meningitis vaccine maker like Sanofi, that's a troubling statistic
Meningitis vaccine maker Sanofi has launched a new initiative that it hopes will increase awareness of the CDC's recommendations for preventing meningococcal meningitis--and give sales a boost in the process.
The U.K.'s Joint Committee on Vaccination and Immunization (JCVI) is revising its stance on Novartis' meningitis B vaccine Bexsero. The jab, originally left off Britain's routine vaccination schedule, has gained the JCVI's nod, supplying a needed boost for the Swiss company's flailing vaccine unit.
Pfizer picked up the FDA's breakthrough therapy designation for an in-development vaccine against meningococcal disease, a common cause of meningitis, lighting the path for an accelerated approval as the drugmaker looks to expand its vaccine portfolio beyond the blockbuster Prevnar 13.